Clinical Trials

One of the unique benefits of being a University of Michigan patient is access to the latest and most promising therapies for cancer. Patients play a vital role by participating in research studies -- also known as clinical trials.

Liver Cancer Trials Currently Enrolling

UMCC 2012.113: Optimization of MRI for Radiation Therapy.
(PI: Shruti Jolly, M.D.) Enrolling

UMCC 2014.065: A Multi-institutional, Single arm, Two-stage Phase II Trial of Nab-paclitaxel and Gemcitabine for First-line Treatment of Patients with Advanced or Metastatic Cholangiocarcinoma.
Sponsor: ECOG (PI: Vaibhav Sahai, M.B.B.S.) Enrolling

UMCC 2012.077: A Phase 1/2 Dose-escalation, open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Advanced Hepatocelluar Carcinoma Subjects with or without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects who are Naïve to Systemic
Sponsor: Bristol-Myers Squibb (PI: Theodore Welling, M.D.) Enrolling.

UMCC 2006.067: A Study of Radiation Toxicity in the Liver Using MRI-Based Perfusion
(PI: Kyle Cuneo, M.D.) Enrolling

UMCC 2003.081: Assessment Of Liver Function in Patients Undergoing Hepatic Irradiation
(PI: Kyle Cuneo, M.D.) Enrolling

UMCC 2015.039: A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma
(PI: Kyle Cuneo, M.D.) Enrolling

HUM00093027: Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed By Sorafenib In Hepatocellular Carcinoma
(PI: Kyle Cuneo, M.D.) Enrolling

SWOG S1310: Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
(PI: Vaibhav Sahai, M.B.B.S.) Enrolling

If you are interested in any of the above trials, please contact the Cancer AnswerLine at 1-800-865-1125.

updated 02.25.2016

back to top